Tesetaxel in Chemotherapy-naive Patients With Progressive, Castration-resistant Prostate Cancer
Status:
Unknown status
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
Given the activity of docetaxel in patients with progressive, metastatic castration-resistant
prostate cancer, this study is being undertaken to evaluate the activity of tesetaxel, an
orally bioavailable taxane, in chemotherapy-naive and chemotherapy-exposed patients.